ketoconazole has been researched along with Kidney Failure in 3 studies
1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of this study was to establish a physiologically based pharmacokinetic (PBPK) model to elucidate in detail the pharmacokinetics of teneligliptin." | 2.80 | Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling. ( Emoto, C; Nakamaru, Y; Shimizu, M; Yamazaki, H, 2015) |
| "Rivaroxaban is a direct oral anticoagulant with a large inter-individual variability." | 1.48 | Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban. ( Ge, W; Jiang, Q; Xu, R, 2018) |
| " The exercise aids in integrating all the knowledge across the drug development to suggest rationale dosing strategies; effectively communicating the impact of the prognostic factors to the clinicians/regulators; and protect against any intellectual losses due to development team changes." | 1.31 | Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application. ( Gobburu, JV; Sekar, VJ, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xu, R | 1 |
| Ge, W | 1 |
| Jiang, Q | 1 |
| Nakamaru, Y | 1 |
| Emoto, C | 1 |
| Shimizu, M | 1 |
| Yamazaki, H | 1 |
| Gobburu, JV | 1 |
| Sekar, VJ | 1 |
1 trial available for ketoconazole and Kidney Failure
| Article | Year |
|---|---|
Human pharmacokinetic profiling of the dipeptidyl peptidase-IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling.
Topics: Adult; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dipeptidyl-Peptidase IV Inhibitors | 2015 |
2 other studies available for ketoconazole and Kidney Failure
| Article | Year |
|---|---|
Application of physiologically based pharmacokinetic modeling to the prediction of drug-drug and drug-disease interactions for rivaroxaban.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Clarithromycin; Computer Simulation; | 2018 |
Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application.
Topics: Computer Simulation; Drug Interactions; Drugs, Investigational; Humans; Investigational New Drug App | 2002 |